logo
Plus   Neg
Share
Email

Novartis Pharma Announces Simultaneous Approval Of Five New Products In Japan

Novartis Pharma K.K. announced that Japanese Ministry of Health, Labour and Welfare has issued simultaneous approval for the company's five new products. Tabrecta, an oral MET inhibitor for MET exon 14 skipping mutation-positive advanced and/or recurrent unresectable non-small cell lung cancer, was approved. The other approved products are: Entresto in chronic heart failure, Mayzent in secondary progressive MS, Enerzair and
Atectura in different forms of asthma.

Kazunari Tsunaba, Representative Director and President of Novartis Pharma, said: "All five medicines are truly novel and transformative treatments and therefore mark an important milestone in our mission to reimagine medicine."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Intel Corp. said it is probing into the hack of its fourth-quarter earnings report that prompted the chipmaker to release its earnings statement ahead of schedule. The company, which was scheduled to release the results after the market closed, released it before the market closing on Thursday. Google parent Alphabet decided to drop its Internet balloon project Loon that was launched with the idea of providing Internet access to rural areas and providing last mile connectivity. In a blog post, Loon CEO Alastair Westgarth said they have not found a way to get the costs low enough to build a long-term, sustainable business, despite gaining a number of interested partners along the way. American Airlines announced the launch of Flagship Cellars, its home delivery service for premium wines usually available onboard. The airline's move is said to be due to the excess wine it has amid the weakness in air travel demand following the coronavirus pandemic crisis. The company expects the new at-home wine program to generate about $40,000 to $50,000 in sales during the first quarter.
Follow RTT